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 Autologous haematopoietic stem cell transplantation (aHSCT) 
is commonly used for the treatment of haematological cancers, 
but is increasingly used in the treatment of patients severely 
affected by autoimmune diseases (ADs). In fact, ADs have 
become the fastest growing indication for aHSCT. A wide range 
of diseases have been treated, but the field has focused on three 
areas: multiple sclerosis, diffuse cutaneous systemic sclerosis 
and Crohn’s disease, where there are populations of patients 
for whom disease control remains unsatisfactory despite the 
advent of biological and targeted small molecule therapies. 
Scientific studies of immune reconstitution have provided 
support for a ‘rebooting’ of the immune system through a 
re-diversification of naive and regulatory immune effector cells. 
In addition, there may be health economic benefits from a 
single one-off procedure. Even so, the treatment with aHSCT 
is intensive with a range of toxicities and risks which, despite 
being routine to transplant haematologists, are less familiar 
to disease specialists. Close collaboration between transplant 
haematologists and relevant disease specialists in patient 
selection, clinical management and follow-up is mandatory. 









 Autologous haematopoietic stem cell transplantation 
(aHSCT) for severe resistant autoimmune and inflammatory 
diseases – a guide for the generalist 
 Key points 
 Autologous HSCT has the potential to induce sustained clinical 
remissions in otherwise resistant or poor prognosis autoimmune 
diseases enabling reduction and even long-term withdrawal of 
immunosuppressive and biological therapies 
 Although a wide range of autoimmune diseases have been 
treated, the evidence base is greatest in relapsing remitting MS, 
diffuse systemic sclerosis and Crohn’s disease 
 Autologous HSCT requires close collaboration between 
experienced transplant haematologists and relevant disease 
specialists in patient selection, management and follow-
up. Early referral of patients is essential to optimise clinical 
outcomes and minimise risks 
 Autologous HSCT may lead to ‘rebooting’ of the immune 
system through regeneration and rediversification of the T and 
B-cell repertoire and increased regulatory T-cell activity 
 There may be health economic benefits to a one-off intensive 
treatment over long-term administration of biological and 
immunosuppressive therapy 
 KEYWORDS: Autoimmune diseases, haematopoietic stem cell 
transplantation, stem cells, autologous, blood and marrow 
transplantation  ! 
 Introduction 
 Haematopoietic stem cell transplantation (HSCT) has evolved 
over the past 50 years to treat a wide range of conditions and is 
now a routine part of clinical haematological practice (Table  1 ). 
Autologous HSCT (aHSCT) is widely used to treat malignant 
diseases such as myeloma and lymphoma. With time, aHSCT has 
become safer and its use has also extended to non-malignant 
diseases, including severe autoimmune diseases (ADs), which is 
now the fastest growing indication for HSCT. 1 
 Clinical studies of aHSCT in ADs have been ongoing since the 
mid-1990s. However, it has taken two decades for aHSCT to be 
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recognised as a treatment option among the evolving array of 
biologic and other modern therapies. More recent evidence has 
supported its use in well-selected patients with ADs, especially 
multiple sclerosis (MS), systemic sclerosis (SSc) and Crohn’s disease 
(CD). 2,3 Consensus recommendations have been published to 
guide judicious patient selection and multidisciplinary practice of 
aHSCT across a range of ADs. 4 – 8 
 Multiple sclerosis 
 Current disease modifying therapies (DMTs) reduce relapse rates 
in patients with relapsing remitting MS (RRMS) but their impact on 
disability is limited. DMTs for progressive MS are scarcely effective 
and early intervention at the inflammatory RRMS phase of this 
illness is therefore key to preventing long-term disability. 9 – 11 
 Autologous haematopoietic stem cell transplantation has been 
used in the treatment of MS since 1995. Initially, patients with 
advanced progressive disease were treated with limited benefit. 9 – 11 
A small phase II randomised controlled trial (RCT) confirmed 
reduced magnetic resonance imaging (MRI) disease activity 
with aHSCT, 12 which strongly supported further phase III studies 
with primary clinical endpoints. There is now increasing evidence 
that its early use in patients with highly active RRMS results in 
significant reduction in clinical and MRI disease activity as well 
as improving patients’ disability to a significantly greater degree 
compared with currently available DMTs. 9 – 11 The recent results 
of the MIST study (ClinicalTrials.gov identifier: NCT00273364), 
which compared the effectiveness of aHSCT against standard 
DMTs, suggests that aHSCT can be safely administered and is 
significantly more effective. 13 However, alemtuzumab, one of the 
most effective DMTs, was not included in the control arm. An RCT 
of aHSCT with alemtuzumab would resolve the question of relative 
efficacy. 
 Outside of clinical trials, current consensus supports the use of 
aHSCT in patients with RRMS who are young (<45 years old), able 
to ambulate independently, have illness duration of <10 years, and 
at least two clinical relapses in the previous year despite the use of 
DMTs with MRI evidence of concurrent disease activity. Patients 
with higher degrees of disability, or occasionally progressive 
disease course, can be considered if there is clear evidence of 
significant clinical and MRI disease activity although the benefit 
in these patients is more limited. Potential patients should be 
discussed with, and treated in, specialised centres with an interest 
in aHSCT for MS. 
 Rheumatological diseases 
 SSc is a multisystem autoimmune connective tissue disease; 
rapidly progressive diffuse cutaneous SSc (dcSSc) has a 
5-year mortality up to 30%. Vasculopathy, excessive collagen 
deposition, inflammation in the skin and internal organs (lung, 
gastrointestinal, cardiovascular and renal) result in fibrosis and 
organ failure, with death most commonly a consequence of 
pulmonary arterial hypertension or interstitial lung disease. 
Effective drug therapy for SSc is lacking; disease-modifying 
antirheumatic drugs (DMARDs) and biologics have failed to show 
lasting benefit; cyclophosphamide over 12 months has shown 
short-term benefit compared with placebo. 4,8,14 – 16 
 Three RCTs in SSc comparing aHSCT to cyclophosphamide 
have been reported: ASSIST, 14 ASTIS 15 and SCOT 16 (Table  2 ). 
All studies compared aHSCT to monthly pulsed intravenous 
 Table 1.  Glossary of terms used in haematopoietic 
stem cell transplantation (HSCT) 
 Types of HSCT 
Autologous 
HSCT (aHSCT)
Transplantation of haematopoietic stem cells 
taken from patients and reinfused after high 
doses of cytotoxic therapy (usually chemotherapy 
with immunoablative therapeutic antibodies such 




Transplantation of haematopoietic stem cells 
from a donor, either sibling or unrelated, and 
occasionally cord blood. Allogeneic HSCT is 
rarely performed for autoimmune diseases 
given the higher risks, and its use has been 
largely restricted to paediatrics




Stem cells, labelled by the antigen CD34+, are 
mobilised using granulocyte colony stimulating 
factor (G-CSF) +/− chemotherapy from the 
bone marrow into the blood then harvested 
with apheresis
Bone marrow Haematopoietic stem cell source derived by direct 
aspiration of bone marrow, a stem cell source 
infrequently used now for autologous HSCT
 HSCT phases 
Mobilisation Mobilisation of CD34+ stem cells from the 
bone marrow into the peripheral blood using 
granulocyte colony stimulating factor (G-CSF) +/− 
chemotherapy. Stem cells are then harvested using 
leukapheresis
Conditioning High dose immunoablative or immunosuppressive 
regimen usually chemotherapy and therapuetic 
antibodies (for example antithymocyte globulin 
[ATG]) administered prior to stem cell infusion
Harvesting Stem cells are harvested using leukapheresis
‘Transplant’/
reinfusion
The thawing and reinfusion of the CD34+ cells 
into the patient
Aplastic phase The period when the immune system and 
haematopoietic system are unable to produce 
sufficient cells to maintain blood counts and 
innate immunity. The combination of antibiotic 
(prophylactic and therapeutic), transfusions, 
symptomatic care, growth factors and close 
monitoring required to bring the patient safely 
through and beyond engraftment, usually 
around 2 weeks post-transplantation
Supportive care The combination of antibiotic (prophylactic 
and therapeutic), transfusions, symptomatic 
care, growth factors and monitoring required 
to bring the patient safely through and beyond 
engraftment, usually around 2 weeks post-
transplantation
Engraftment Defined as 3 days of neutrophils rising above 
0.5 × 10 9 /L and/or platelets rising above 
20 × 10 9 /L unsupported
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cyclophosphamide. ASSIST randomised patients to aHSCT or 
cyclophosphamide for 6 months and 19 patients were followed 
for 2 years. There was a significant improvement in respiratory 
and cutaneous disease in the aHSCT group with no transplant 
related mortality (TRM) reported. ASTIS compared aHSCT to 
cyclophosphamide for 12 months in 156 patients with early dcSSc 
and a median follow-up of 5.8 years. The primary endpoint was 
event-free survival (time from randomisation until the death 
or persistent major organ failure). In the aHSCT arm there 
were 22 events including 19 deaths (TRM 10%) predominantly 
attributed to SSc-related cardiac dysfunction. Long-term 
event-free and overall survival rates were higher with aHSCT. 
SCOT randomised 75 patients with severe SSc to aHSCT versus 
cyclophosphamide for 12 months, followed up for 4.5 years. The 
primary endpoint was a global rank composite score (GRCS) based 
on a hierarchy of disease features. AHSCT resulted in significantly 
better clinical outcomes compared with cyclophosphamide, with 
fewer events of conditioning-associated cardiac toxicity and TRM 
was reduced compared with ASTIS. 
 Improvements in disease control and long-term survival make 
aHSCT in selected patients with SSc increasingly attractive. Given 
that pre-existing pulmonary vascular and cardiac involvement 
are major contributors to TRM risk, an extensive cardiothoracic 
evaluation is mandatory for appropriate patient selection. 5 
 AHSCT has also been used successfully in the treatment of 
other severe autoimmune connective tissue diseases including 
systemic lupus erythematosus (SLE), 17 rheumatoid and other 
inflammatory arthritides, dermato- and polymyositis and systemic 
vasculitis. 3,4 However, in contrast to SSc, the success of standard 
immunomodulatory treatments and newer biological therapies 
in the management of these diseases has been such that in 
practice aHSCT is only considered for those individuals with severe 
recalcitrant disease. 
 Crohn’s disease 
 Despite advances in conventional and biological therapies, 
a substantial minority of CD patients experience treatment 
refractory disease that results in a marked reduction in quality 
of life, leaving such individuals with limited therapeutic options. 
Surgical resection may not be feasible or may be declined by the 
patient if it will result in a permanent stoma. 6 
 Initial case series and single-centre cohort studies suggested 
that aHSCT could induce sustained clinical benefit. To date there 
has only been one randomised controlled trial to assess the 
value of aHSCT in refractory CD, the ASTIC trial 18 (see Table  3 ). 
ASTIC was a negative trial partly due to a very ambitious 
primary endpoint, and partly as the control arm also delivered a 
significant dose of cyclophosphamide for stem cell mobilisation 
resulting in transient reduction in clinical disease activity. Patients 
randomised to the control group in ASTIC could undergo aHSCT 
after the primary endpoint had been assessed and underwent 
the same schedule of assessments over the subsequent year. 
When analysed as the combined cohort of all 40 patients that 
underwent aHSCT, there were significant improvements in clinical 
disease activity, quality of life and endoscopic disease activity 
after one year; 50% of this group had complete mucosal healing, 
an important endpoint in CD and associated with improved long-
term outcomes. 19 
 Long-term outcomes after aHSCT are also reported in single-
centre and registry cohorts. Significantly, the majority of 
 Table 2.  Registrations in the EBMT Registry for 
autologous HSCT in autoimmune diseases (n=2515), 
June 2018* 
 Multiple sclerosis  1228 







 Arthritis  166 
Rheumatoid arthritis 80
Juvenile chronic arthritis:
 Systemic JIA 46
 Other JIA 18
 Polyarticular JIA 12
Psoriatic arthritis 3
Other 7




 Haematological  51 
Immune thrombocytopenia 27
Evans’ syndrome 8
Autoimmune haemolytic anaemia 12
Other 4















 Type 1 diabetes  20 
 Other/unknown  18 
 *EBMT registry accessed 4 June 2018. 
 CIDP = Chronic inflammatory demyelinating polyneuropathy ; HUVS = 











































 Table 3.  Randomised controlled trials of autologous HSCT in autoimmune diseases 




Conditioning regimen Comparator arm Results Reference 
(number) 
MS ASTIMS 21 Cy 4 g/m 2 + G-CSF BEAM + rATG Mitoxantrone + methylprednisolone 
 monthly for 6 months
aHSCT significantly superior to 
mitoxantrone in reducing MRI activity 
in severe MS (79% reduction in T2 
lesions). No difference in disease 
progression. No TRM
12
MS MIST 110 
 Interim 
analysis
Cy 2 g/m 2 + G-CSF Cy 200 mg/kg + rATG Standard of DMT care (interferons, 
glatiramer acetate, dimethyl fumarate, 
fingolimod, natalizumab, but not 
alemtuzumab),
aHSCT statistically superior to continued 
DMTs in terms of disability scores (EDSS) 
and progression in patients with RRMS 
with >2 relapses a year. No TRM
13
SSc ASSIST 19 Cy 2 g/m 2 + G-CSF Cy 200 mg/kg + rATG Cy 1 g/m 2 monthly for 6 months All aHSCT (10/10) patients improved in 
skin score and lung function at 12 months 
compared to 0/9 in control. No TRM
14
SSc ASTIS 156 Cy 4 g/m 2 + G-CSF Cy 200 mg/kg + rATG Cy 750 mg/m 2  monthly for 12 months EFS and OS favoured aHSCT at 5.8 years. 
TRM 10%
15
SSc SCOT 75 G-CSF Cy 200 mg/kg + hATG + 
TBI 800 cGy (with lung 
and kidney shielding)
Cy 500 mg/m 2 for 1 month, then 750 mg/
m 2 for 11 months
Superiority of aHSCT for GRCS (at 54 
months), and EFS and OS (at 72 months). 
TRM 3% at 54 months and 6% at 
72 months. Three malignancies in aHSCT 
group (possibly TBI related) compared 
with one in control group
16
CD ASTIC 45 Cy 4 g/m 2 + G-CSF Cy 200 mg/kg + rATG Early versus late aHSCT Failed primary endpoint (sustained 
clinical remission off medication with no 
evidence of active disease on endoscopy 





38 Cy 4 g/m 2 + G-CSF Cy 200 mg/kg + rATG Open label cohort of all patients undergoing 
aHSCT in ASTIC trial
3 months steroid-free remission at 1 year: 
38%, 95% CI 22–55. Complete endoscopic 
healing: 50%, 95% CI 34–66
19
 ASSIST = American Scleroderma Stem Cell versus Immune Suppression Trial; ASTIC = Autologous Stem Cell Transplantation International Crohn’s disease; ASTIMS = Autologous Stem Cell Transplantation International MS; ASTIS = 
Autologous Stem Cell Transplantation International Scleroderma; BEAM = BCNU/Etoposide/ARA-C/Melphalan; Cy = cyclophosphamide; EDSS = expanded disability status scale; EFS = event-free survival; G-CSF = granulocyte colony-
stimulating factor; GRCS = global rank composite score; hATG = horse antithymocyte globulin; MIST = Multiple Sclerosis International Stem cell Transplant trial; OS = overall survival; rATG = rabbit antithymocyte globulin; SCOT = 
Scleroderma: Cyclophosphamide or Transplantation; TBI = total body irradiation; TRM = transplant-related mortality 
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patients who relapsed after aHSCT subsequently responded to 
reintroduction of anti-TNF therapy. 6,20 
 Further research is required to assess the place of aHSCT in the 
management of patients with treatment refractory and poor 
prognosis CD. ASTIClite is an NIHR-funded randomised controlled 
trial that will assess the benefit and risks of a low intensity 
mobilisation and conditioning HSCT regimen compared to the 
best currently available medical care in patients with significant 
CD refractory to at least two classes of biologic therapy. The 
primary endpoint will be mucosal healing, and patients who are 
randomised to HSCT but have disease recurrence at 6 months will 
restart anti-TNF therapy. 21 
 Other diseases 
 A variety of other autoimmune diseases have been treated with 
aHSCT and are summarised in Table  2 . In these rarer disease 
indications, it has been challenging to conduct large-scale clinical 
trials, at least of the randomised type, and this is where the 
transplant registries have been especially useful. Outcomes of HSCT 
in these indications can be accessed via recent reviews of the field. 3,4 
 Mechanisms of action 
 In the early stages the administration of high doses of cytotoxic 
therapy has a profound anti-inflammatory effect (see Fig  1 , 
under ‘aHSCT ablation’). Subsequently, post-transplant immune 
reconstitution studies have supported re-diversification of T-cell 
repertoire, with quantitative and qualitative changes in T-regulatory 
cell numbers (see Fig  1 , under ‘aHSCT reconstitution’). Other 
immune compartments, such as naive B cells and NK cells may also 
be regenerated. Effects on the adaptive immune system persist well 
beyond the transplant period and the lymphocyte repopulation 
phase, supporting the notion of an immune reset or reboot. In 
addition to providing insights on immune reconstitution, concurrent 
scientific studies conducted while destroying and rebuilding 
dysfunctional immune systems may also provide useful insights into 
the aetiology and pathogenesis of autoimmune diseases. 7,11,21 
 Conclusions 
 Autologous HSCT has been used in a wide range of AD clinical 
settings but the field has focused on three areas in which disease 
control remains unsatisfactory despite the advent of biologicals 
and other modern immunomodulatory therapies: MS, diffuse 
cutaneous SSc and CD. There may be health economic benefits 
from a single one-off procedure versus years of ongoing biological 
treatment. Even so, treatment with aHSCT is intensive with a range 
of significant risks and toxicities, which, despite being routine to 
transplant haematologists, have variable acceptability to disease 
specialists. Close collaboration between transplant haematologists 
and relevant disease specialists is essential in patient selection, 
clinical management and follow-up. Early referral of patients, 
where there is good general fitness as well as the potential of 
tissue damage reversibility is essential to achieve the best clinical 
outcomes while minimising the risks of toxicity. Ideally, patients 
should be treated on a clinical trial or at least their data submitted 
to a transplant registry. Concurrent scientific studies will help 
elucidate the mechanism of action while shedding light on the 
underlying pathogenesis of ADs. ! 
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 Fig 1.  Potential mechanisms of 
action of aHSCT in autoim-
mune diseases. In individuals 
with genetic susceptibility towards 
autoimmune disease, exposure to 
multiple environmental factors 
such as viral infection and toxic or 
metabolic damage (top), may 
induce autoimmune disease 
through aberrant antigen (Ag) 
mediated activation of T cells 
(centre). In aHSCT the cytotoxic 
chemotherapy ablates the 
lymphoid system including T 
lymphocyte immunity (as 
depicted). The leukocyte 
depletion enables an immune 
reconstitution that restores the 
predominance of anti-infl amma-
tory regulating factors (bottom 
left) over infl ammatory effectors 
(bottom right). These mecha-
nisms may explain induction of 
long-lasting suppression of some 
autoimmune diseases by aHSCT. 
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